Irinotecan as Maintenance Therapy in High-Risk Hepatoblastoma

被引：20

作者：

Qayed, Muna ^{[1
,2
]}

Powell, Christie ^{[1
,2
]}

Morgan, Elaine R. ^{[3
,4
]}

Haugen, Maureen ^{[3
,4
]}

Katzenstein, Howard M. ^{[1
,2
]}

机构：

[1] Emory Univ, Aflac Canc Ctr, Div Pediat Hematol Oncol, Atlanta, GA 30322 USA

[2] Childrens Healthcare Atlanta, Atlanta, GA USA

[3] Childrens Mem Hosp, Div Pediat Hematol Oncol, Chicago, IL 60614 USA

[4] Northwestern Univ, Chicago, IL 60611 USA

来源：

PEDIATRIC BLOOD & CANCER | 2010年 / 54卷 / 05期

关键词：

hepatoblastoma; irinotecan; maintenance; PEDIATRIC-ONCOLOGY-GROUP; REFRACTORY SOLID TUMORS; PHASE-I TRIAL; ORAL IRINOTECAN; CHILDREN; DOXORUBICIN; INHIBITORS; TOPOTECAN; SCHEDULE; MICE;

D O I：

10.1002/pbc.22408

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Children with high-risk hepatoblastoma (metastatic disease or a low alpha-fetoprotein at presentation) and those with recurrent disease have an extremely poor prognosis and are in need of novel therapeutic agents and strategies. We describe three patients who were treated with irinotecan (two in combination with vincristine). In two patients, this contributed to a clinical remission. All three patients received a 1- to 2-year course of irinotecan as maintenance therapy and all remain disease free. Treatment was well tolerated with minimal toxicity. Further evaluation of the use of irinotecan as maintenance therapy in high-risk and recurrent HB patients is warranted. Pediatr Blood Cancer 2010;54:761-763. (c) 2010 Wiley-Liss, Inc.

引用

页码：761 / 763

页数：3

共 17 条

[1] Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma [J].

Bisogno, G ;

Riccardi, R ;

Ruggiero, A ;

Arcamone, G ;

Prete, A ;

Surico, G ;

Provenzi, M ;

Bertolini, P ;

Paolucci, P ;

Carli, M .

CANCER, 2006, 106 (03) :703-707

[2]

Blaney S, 2001, CLIN CANCER RES, V7, P32

[3] Phase II trial of irinotecan in children with refractory solid tumors: A children's oncology group study [J].

Bomgaars, Lisa R. ;

Bernstein, Mark ;

Krailo, Mark ;

Kadota, Richard ;

Das, Soma ;

Chen, Zhengjia ;

Adamson, Peter C. ;

Blaney, Susan M. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (29) :4622-4627

[4] Cefixime allows greater dose escalation of oral irinotecan: A phase I study in pediatric patients with refractory solid tumors [J].

Furman, WL ;

Crews, KR ;

Billups, C ;

Wu, JR ;

Gajjar, AJ ;

Daw, NC ;

Patrick, CC ;

Rodriguez-Galindo, C ;

Stewart, CF ;

Dome, JS ;

Panetta, JC ;

Houghton, PJ ;

Santana, VM .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (04) :563-570

[5] Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children [J].

Furman, WL ;

Stewart, CF ;

Poquette, CA ;

Pratt, CB ;

Santana, VM ;

Zamboni, WC ;

Bowman, LC ;

Ma, MK ;

Hoffer, FA ;

Meyer, WH ;

Pappo, AS ;

Walter, AW ;

Houghton, PJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (06) :1815-1824

[6] Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan [J].

Gupta, Anshul ;

Dai, Yang ;

Vethanayagam, R. Robert ;

Hebert, Mary F. ;

Thummel, Kenneth E. ;

Unadkat, Jashvant D. ;

Ross, Douglas D. ;

Mao, Qingcheng .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (03) :374-383

[7]

HOUGHTON PJ, 1995, CANCER CHEMOTH PHARM, V36, P393

[8] Novel therapeutic approaches in the treatment of children with hepatoblastoma [J].

Katzenstein, HM ;

Rigsby, C ;

Shaw, PH ;

Mitchell, TL ;

Haut, PR ;

Kletzel, M .

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2002, 24 (09) :751-755

[9] Treatment of unresectable and metastatic hepatoblastoma: A pediatric oncology group phase II study [J].

Katzenstein, HM ;

London, WB ;

Douglass, EC ;

Reynolds, M ;

Ploschkes, J ;

Finegold, MJ ;

Bowman, LC .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (16) :3438-3444

[10] Redefining the role of doxorubicin for the treatment of children with hepatoblastoma [J].

Malogolowkin, Marcio H. ;

Katzenstein, Howard M. ;

Krailo, Mark ;

Chen, Zhengjia ;

Quinn, John J. ;

Reynolds, Marleta ;

Ortega, Jorge A. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (14) :2379-2383

← 1 2 →